Elena G Kornetova

List of Publications by Year
in descending order

49	386	840776 11	839539 18
papers	citations	h-index	g-index

57	57	57	395
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 475-481.	4.8	53
2	Missense polymorphisms in three oxidativeâ€stress enzymes (GSTP1, SOD2, and GPX1) and dyskinesias in Russian psychiatric inpatients from Siberia. Human Psychopharmacology, 2010, 25, 84-91.	1.5	34
3	Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia. Heliyon, 2019, 5, e02033.	3.2	34
4	The difference in serum proteomes in schizophrenia and bipolar disorder. BMC Genomics, 2019, 20, 535.	2.8	27
5	Prolactin gene polymorphism (â˜' 1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. Schizophrenia Research, 2017, 182, 110-114.	2.0	24
6	Adipocytokines and Metabolic Syndrome in Patients with Schizophrenia. Metabolites, 2020, 10, 410.	2.9	19
7	Changes in Body Fat and Related Biochemical Parameters Associated With Atypical Antipsychotic Drug Treatment in Schizophrenia Patients With or Without Metabolic Syndrome. Frontiers in Psychiatry, 2019, 10, 803.	2.6	18
8	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. BMC Medical Genetics, 2019, 20, 47.	2.1	17
9	Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms. Life, 2021, 11, 997.	2.4	17
10	Cytokine Level Changes in Schizophrenia Patients with and without Metabolic Syndrome Treated with Atypical Antipsychotics. Pharmaceuticals, 2021, 14, 446.	3.8	15
11	Global hypomyelination of the brain white and gray matter in schizophrenia: quantitative imaging using macromolecular proton fraction. Translational Psychiatry, 2021, 11, 365.	4.8	14
12	Cortisol and DHEAS Related to Metabolic Syndrome in Patients with Schizophrenia . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1051-1058.	2.2	12
13	Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. Journal of Personalized Medicine, 2021, 11, 181.	2.5	11
14	Igg-Dependent Hydrolysis of Myelin Basic Protein of Patients with Different Courses of Schizophrenia. Journal of Immunology Research, 2020, 2020, 1-12.	2.2	10
15	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. Frontiers in Molecular Neuroscience, 2020, 13, 63.	2.9	9
16	Body Fat Parameters, Glucose and Lipid Profiles, and Thyroid Hormone Levels in Schizophrenia Patients with or without Metabolic Syndrome. Diagnostics, 2020, 10, 683.	2.6	8
17	Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia . The Application of Clinical Genetics, 2020, Volume 13, 97-105.	3.0	7
18	Amino Acid and Acylcarnitine Levels in Chronic Patients with Schizophrenia: A Preliminary Study. Metabolites, 2021, 11, 34.	2.9	7

#	Article	IF	Citations
19	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. Frontiers in Psychiatry, 2021, 12, 661174.	2.6	7
20	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 1123-1131.	0.7	7
21	Genetic polymorphisms of PIP5K2A and course of schizophrenia. BMC Medical Genetics, 2020, 21, 171.	2.1	4
22	Association of ANKK1 polymorphism with antipsychoticâ€induced hyperprolactinemia. Human Psychopharmacology, 2020, 35, e2737.	1.5	4
23	A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 110134.	4.8	4
24	Morphophenotypic predictor of the development of visceral obesity in patients with schizophrenia receiving antipsychotic therapy. Bulletin of Siberian Medicine, 2018, 17, 54-64.	0.3	4
25	Neurocognitive deficits in clinical polymorphism of schizophrenia: typology, expression and syndromal overlaps. Bulletin of Siberian Medicine, 2019, 18, 107-118.	0.3	3
26	Efficacy and tolerability of system isotretinoin and effect of this therapy on the quality of life of patients with severe and moderate acne. Vestnik Dermatologii I Venerologii, 2021, 97, 70-80.	0.6	2
27	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. Genes, 2022, 13, 844.	2.4	2
28	1585 â€“ Social adaptation and immune reactivity in schizophrenia. European Psychiatry, 2013, 28, 1.	0.2	1
29	Brain pathology in schizophrenia: association with clinical and constitutional factors. Ã‚kutskij Medicinskij Å¾urnal, 2019, , 17-21.	0.1	1
30	Sexual differences in the clinical features of antipsychotic-induced hyperprolactinemia in patients with schizophrenia. Bulletin of Siberian Medicine, 2019, 18, 62-71.	0.3	1
31	Is there constitutional and morphological predisposition to akathisia in schizophrenic patients receiving antipsychotic therapy?. Bulletin of Siberian Medicine, 2020, 18, 36-43.	0.3	1
32	ÐœÐ¾ÐÐµÐ»ÑŒ Ð¿Ñ€Ð¾Ð³Ð½Ð¾Ð·Ð¸Ñ€Ð¾Ð²Ð°Ð½Ð¸Ñ•Ð¼ÐµÑ‚Ð°Ð±Ð¾Ð»Ð¸Ñ‡ÐµÑ•ÐºÐ¾Ð³Ð¾ ÑÐ¸Ð½Ð´Ñ€Ð¾Ð¼Ð° Ñƒ Ð		
33	Metabolic Syndrome in a Population of In-Patients with Schizophrenia in the Western Siberia. Psychiatry, 2021, 19, 52-60.	0.7	1
34	Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia. Diagnostics, 2022, 12, 1521.	2.6	1
35	1831 â€“ Dnase and protease activity of immunoglobulins G of patients with schizophrenia. European Psychiatry, 2013, 28, 1.	0.2	0
36	P.876 The effect of atypical antipsychotic therapy on hormonal and biochemical parameters in patients with schizophrenia. European Neuropsychopharmacology, 2019, 29, S583-S584.	0.7	0

#	Article	IF	Citations
37	P.390 Characteristics of metabolic hormones in patients with schizophrenia with antipsychotic-induced metabolic syndrome. European Neuropsychopharmacology, 2019, 29, S276-S277.	0.7	0
38	P.568 Trihexyphenidyl in combination with antipsychotic therapy does not affect the severity of neurocognitive deficits in patients with schizophrenia. European Neuropsychopharmacology, 2020, 40, S322-S323.	0.7	0
39	Cognitive functions and a BDNF gene polymorphism in schizophrenia patients and healthy individuals. , 2020, , .		0
40	COMT gene polymorphism and antipsychotic- induced hyperprolactinemia in schizophrenia patients. , 2020, , .		0
41	Relationship Between Social Adaptation Self-Evaluation and Suicide Risk in Patients with Schizophrenia. Psychiatry, 2021, 19, 34-40.	0.7	0
42	PSYCHOMETRIC EVALUATION OF SYMPTOMS AND CLINICAL DYNAMICS OF SCHIZOPHRENIA IN DEPENDING ON CONSTITUTIONALLY-MORPHOLOGICAL TYPE OF THE PATIENTS. Bulletin of Siberian Medicine, 2016, 15, 58-64.	0.3	0
43	Ð¡Ð²ÑÐ·ÑŒ ÑÑƒÐ¸Ñ†Ð¸Ð´Ð°Ð»ÑŒÐ½Ð¾Ð³Ð¾ Ð¿Ð¾Ð²ÐµÐ´ÐµÐ½Ð¸Ñ•Ð¸ Ð±ÐµÐ·Ð½Ð°Ð´ÐµÐ¶Ð½Ð¾ÑÑ‚Ð¸ ÑÐ²ÐºÐ°Ñ‚Ð¸Ð·Ð¸Ðµ	0.2	0
44	Ð¡ÑƒÐ¸Ñ†Ð¸Ð´Ð°Ð»ÑŒÐ½Ð¾Ðµ Ð¿Ð¾Ð²ÐµÐ´ÐµÐ½Ð¸Ðµ Ð±Ð¾Ð»ÑŒÐ½Ñ‹Ñ… ÑˆÐ¸Ð·Ð¾Ñ„Ñ€ÐµÐ½Ð¸ÐµÐ¹ Ñ•Ð¼ÐµÑÐ°Ð±Ð¾Ð	0.2	0
45	Ð'Ð»Ð¸ÑÐ½Ð¸Ðµ ÐºÐ¾Ð³Ð½Ð¸Ñ‚Ð¸Ð²Ð½Ñ‹Ñ… Ñ„ÑƒÐ½ÐºÑ†Ð¸Ð¹ Ð½Ð° ÑƒÑ€Ð¾Ð²ÐµÐ½ÑŒ ÑÑƒÐ¸Ñ†Ð¸Ð´Ð°Ð»ÑŒÐ½Ð¾Ð³Ð¾	0.2	0
46	The Role of Antypsychotic Therapy in the Development of Akathisia in Patients with Schizophrenia. Psychiatry, 2020, 18, 32-38.	0.7	0
47	Influence of clinical and therapeutic indicators on the severity of neurocognitive deficits in patients with schizophrenia. Bulletin of Siberian Medicine, 2020, 19, 36-43.	0.3	0
48	Molecular genetic study of clinical and cognitive features of schizophrenia: No associations with genes SOD2, GSTO1, NQO1. Sibirskij Å¾urnal KliniÄeskoj I Ã¨ksperimentalÊ¹noj Mediciny, 2022, 36, 99-106.	0.4	0
49	The effect of antipsychotic-induced extrapyramidal disorders on patientâ€™s compliance with schizophrenia (a clinical case). Bulletin of Siberian Medicine, 2022, 20, 211-217.	0.3	0